PK/PD models in antibacterial development

Current Opinion in Microbiology

Volumn 16, Issue 5, 2013, Pages 573-579

  Velkov, Tony ^a   Bergen, Phillip J ^a   Lora Tamayo, Jaime ^a,b   Landersdorfer, Cornelia B ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAROLINE FOSAMIL; CYCLOPHOSPHAMIDE; LINEZOLID; PLAZOMICIN;

BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BIOFILM; CLINICAL TRIAL; HUMAN; IN VITRO STUDY; NONHUMAN; RESERVOIR; REVIEW; SEPTICEMIA; URINARY TRACT INFECTION; WOUND INFECTION;

ANIMALIA; BACTERIA (MICROORGANISMS);

ANIMAL EXPERIMENTATION; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; MICROBIAL SENSITIVITY TESTS;

EID: 84887620265     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2013.06.010     Document Type: Review

References (53)

1. Infectious Diseases Society of America The 10×'20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010, 50:1081-1083.
2. Gloede J., Scheerans C., Derendorf H., Kloft C. In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother 2010, 65:186-201.
3. Lister P.D. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. Biochem Pharmacol 2006, 71:1057-1065.
4. Budha N.R., Lee R.B., Hurdle J.G., Lee R.E., Meibohm B. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinb) 2009, 89:378-385.
5. Cadwell J.J.S. The hollow fibre infection model for antimicrobial pharmacodynamics and pharmacokinetics. Adv Pharmacoepiderm Drug Safety 2012, S1:007.
6. Bergen P.J., Bulitta J.B., Forrest A., Tsuji B.T., Li J., Nation R.L. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 2010, 54:3783-3789.
7. Garonzik S.M., Li J., Thamlikitkul V., Paterson D.L., Shoham S., Jacob J., Silveira F.P., Forrest A., Nation R.L. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55:3284-3294.
8. Nicasio A.M., Bulitta J.B., Lodise T.P., D'Hondt R.E., Kulawy R., Louie A., Drusano G.L. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model. Antimicrob Agents Chemother 2012, 56:682-686.
9. Singh R., Tam V.H. Optimizing dosage to prevent emergence of resistance-lessons from in vitro models. Curr Opin Pharmacol 2011, 11:453-456.
10. Drusano G.L., Sgambati N., Eichas A., Brown D.L., Kulawy R., Louie A. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. MBio 2010, 1:e00139-210.
11. Bergen P.J., Tsuji B.T., Bulitta J.B., Forrest A., Jacob J., Sidjabat H.E., Paterson D.L., Nation R.L., Li J. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011, 55:5685-5695.
12. Deris Z.Z., Yu H.H., Davis K., Soon R.L., Jacob J., Ku C.K., Poudyal A., Bergen P.J., Tsuji B.T., Bulitta J.B., et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2012, 56:5103-5112.
13. Tam V.H., Louie A., Deziel M.R., Liu W., Drusano G.L. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 2007, 51:744-747.
14. Drusano G.L., Louie A., Deziel M., Gumbo T. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis 2006, 42:525-532.
15. Bergen P.J., Li J., Nation R.L., Turnidge J.D., Coulthard K., Milne R.W. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008, 61:636-642.
16. Mouton J.W., Brown D.F., Apfalter P., Canton R., Giske C.G., Ivanova M., MacGowan A.P., Rodloff A., Soussy C.J., Steinbakk M., et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012, 18:E37-E45.
17. Bulitta J.B., Landersdorfer C.B., Forrest A., Brown S.V., Neely M.N., Tsuji B.T., Louie A. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol 2011, 12:2044-2061.
18. Vaddady P.K., Lee R.E., Meibohm B. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Med Chem 2010, 2:1355-1369.
19. Stewart P.S., Costerton J.W. Antibiotic resistance of bacteria in biofilms. Lancet 2001, 358:135-138.
20. Coenye T., Nelis H.J. In vitro and in vivo model systems to study microbial biofilm formation. J Microbiol Methods 2010, 83:89-105.
21. Goeres D.M., Hamilton M.A., Beck N.A., Buckingham-Meyer K., Hilyard J.D., Loetterle L.R., Lorenz L.A., Walker D.K., Stewart P.S. A method for growing a biofilm under low shear at the air-liquid interface using the drip flow biofilm reactor. Nat Protoc 2009, 4:783-788.
22. Kim J., Park H.D., Chung S. Microfluidic approaches to bacterial biofilm formation. Molecules 2012, 17:9818-9834.
23. Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999, 37:1771-1776.
24. Chavant P., Gaillard-Martinie B., Talon R., Hebraud M., Bernardi T. A new device for rapid evaluation of biofilm formation potential by bacteria. J Microbiol Methods 2007, 68:605-612.
25. Furustrand Tafin U., Corvec S., Betrisey B., Zimmerli W., Trampuz A. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother 2012, 56:1885-1891.
26. Schwartz K., Stephenson R., Hernandez M., Jambang N., Boles B.R. The use of drip flow and rotating disk reactors for Staphylococcus aureus biofilm analysis. J Vis Exp 2010, 46:e2470.
27. Goeres D.M., Loetterle L.R., Hamilton M.A., Murga R., Kirby D.W., Donlan R.M. Statistical assessment of a laboratory method for growing biofilms. Microbiology 2005, 151:757-762.
28. Hannig C., Follo M., Hellwig E., Al-Ahmad A. Visualization of adherent micro-organisms using different techniques. J Med Microbiol 2010, 59:1-7.
29. Daddi Oubekka S., Briandet R., Fontaine-Aupart M.P., Steenkeste K. Correlative time-resolved fluorescence microscopy to assess antibiotic diffusion-reaction in biofilms. Antimicrob Agents Chemother 2012, 56:3349-3358.
30. McLean J.S., Ona O.N., Majors P.D. Correlated biofilm imaging, transport and metabolism measurements via combined nuclear magnetic resonance and confocal microscopy. ISME J 2008, 2:121-131.
31. Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002, 19:261-268.
32. Cars O., Odenholt-Tornqvist I. The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother 1993, 31(Suppl D):159-166.
33. Craig W.A., Redington J., Ebert S.C. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991, 27(Suppl C):29-40.
34. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W.A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988, 158:831-847.
35. Andes D., Craig W.A. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006, 50:1376-1383.
36. Andes D., van Ogtrop M.L., Peng J., Craig W.A. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002, 46:3484-3489.
37. Drusano G.L., Johnson D.E., Rosen M., Standiford H.C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993, 37:483-490.
38. Reyes N., Aggen J.B., Kostrub C.F. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob Agents Chemother 2011, 55:1728-1733.
39. Cremieux A.C., Maziere B., Vallois J.M., Ottaviani M., Azancot A., Raffoul H., Bouvet A., Pocidalo J.J., Carbon C. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989, 159:938-944.
40. Durack D.T., Beeson P.B. Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations. Br J Exp Pathol 1972, 53:50-53.
41. Andes D.R., Craig W.A. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis 1998, 27:47-50.
42. Sobel J.D. Bacterial etiologic agents in the pathogenesis of urinary tract infection. Med Clin North Am 1991, 75:253-273.
43. Andriole V.T. Urinary tract infections in the 90s: pathogenesis and management. Infection 1992, 20(Suppl 4):S251-S256.
44. Rubin R.H., Shapiro E.D., Andriole V.T., Davis R.J., Stamm W.E. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992, 15(Suppl 1):S216-S227.
45. Hopkins W.J., Hall J.A., Conway B.P., Uehling D.T. Induction of urinary tract infection by intraurethral inoculation with Escherichia coli: refining the murine model. J Infect Dis 1995, 171:462-465.
46. Dai T., Kharkwal G.B., Tanaka M., Huang Y.Y., Bil de Arce V.J., Hamblin M.R. Animal models of external traumatic wound infections. Virulence 2011, 2:296-315.
47. Fallon M.T., Shafer W., Jacob E. Use of cefazolin microspheres to treat localized methicillin-resistant Staphylococcus aureus infections in rats. J Surg Res 1999, 86:97-102.
48. Williams D.L., Costerton J.W. Using biofilms as initial inocula in animal models of biofilm-related infections. J Biomed Mater Res B Appl Biomater 2012, 100:1163-1169.
49. Dalton T., Dowd S.E., Wolcott R.D., Sun Y., Watters C., Griswold J.A., Rumbaugh K.P. An in vivo polymicrobial biofilm wound infection model to study interspecies interactions. PLoS ONE 2011, 6:e27317.
50. Zhang H., Kalkeri G., Mani N., Grossman T.H. Development and validation of a multi-dose neutropenic rat thigh infection model using real-time monitoring of Staphylococcus aureus growth in vivo. In Vivo 2008, 22:667-672.
51. Xiong Y.Q., Willard J., Kadurugamuwa J.L., Yu J., Francis K.P., Bayer A.S. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob Agents Chemother 2005, 49:380-387.
52. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., Drusano G.L. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007, 44:79-86.
53. Landersdorfer C.B., Ly N.S., Xu H., Tsuji B.T., Bulitta J.B. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother 2013, 57:2343-2351.